1961-2011: Fifty years of constant and united commitment in the fight against cancer, serving patients. As early as 1961, the fundamental missions promoted by Dr. Vincent Paschetta, founding director of the “Centre Anticancรฉreux de Nice,” were sealed: DETECT, TREAT, HUMANIZE.
These are the three axes that successive administrations have continually developed over the years. An establishment proud of its past and that has demonstrated constant evolution. Today, CAL boasts three buildings, a modern technical platform, certified research teams, and specialized professionals. It is strongly committed to its teaching mission with the University.
CAL has managed to adapt to the demands related to cancer pathology and become a reference center offering patients specific treatments, notably in head and neck cancers and breast cancers, providing comprehensive care.
Its evolution has been marked by the organization of a unique radiotherapy department in France, by the development of targeted medical therapies for cancer, and finally, by individualized and comprehensive patient care at all stages of the disease.
An informed, listened to, and empowered patient in their treatment, as Ben writes to support and illustrate this fiftieth anniversary: “I want to heal.”
Today, 50% of cancers are cured, the fight must continue, and CAL is leading new projects:
– Creation of a Breast Clinic for rapid management of breast diseases.
– Upcoming opening, in partnership with the CHU of Nice, of the Institut Universitaire de la Face et du Cou.
– Creation of a Research Center with UNS, INSERM, CNRS; on the theme of Cancer and Aging.
– Creation of a High Energy Proton Therapy Center (care and research project).
– Generosity for the benefit of Research: 5 charity concerts to celebrate CAL’s 50th anniversary.
CAL’s Friends, which include the City of Nice, the Rotary Club Maeterlinck, CEDAC, the White Penitents, and many regional volunteer artists, have made these 5 events possible, which will help raise funds to advance cancer research.
                                    
